한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
in recent years, the chinese government has actively introduced some policies to promote the research and development of rare disease drugs and industrial development. for example, the "14th five-year plan" for the development of the pharmaceutical industry, the implementation plan for supporting the development of innovative drugs across the entire supply chain, and the guiding principles for the study of the natural history of diseases in the development of rare disease drugs have all provided important technical guidance and support for the research and development of rare disease drugs. however, these policies are only basic guarantees and have not really promoted the development of the industry.
the title of "orphan drug" has been used to describe the research and development and industry of rare disease drugs. due to the high research and development costs, small market capacity and low return on investment, companies are often reluctant to make it a research and development focus or even give up on research and development. this has led to the stagnation of the innovative development of rare disease drugs.
solving the "orphan drug" problem requires joint efforts from the government and enterprises, and integrating existing policies through legislation to form a joint support mechanism. the government can use cash rewards or tax reductions to stimulate pharmaceutical and medical device companies to invest in the production of rare disease products. at the same time, extending the data protection period and market exclusivity period for rare disease drugs and medical devices, and accelerating the listing of rare disease drugs and medical devices in various forms will bring more protection to patients and provide more impetus for industrial development.
in addition, the government needs to set up a special medical insurance fund to cover rare diseases, integrate forces from all walks of life to participate in the financing and operation of the special fund, and encourage local governments to explore special funds for rare diseases or other innovative payment models. this will help to effectively meet the medical needs of patients with rare diseases and find new breakthroughs in industrial development.
however, all this requires the joint efforts of the government and enterprises, and the persistence of long-term support for the development of the rare disease drug industry. i believe that with the implementation of policies and the continuous development of the industry, the research and development of rare disease drugs and industrial development will make greater progress, and ultimately bring hope to more patients.
